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Several studies have demonstrated the eﬃcacy of intraprostatic injection of botulinum neurotoxin type 
A (BoNT/A) against symptomatic benign prostatic hyperplasia (BPH).  The most commonly used 
BoNT/A product,  Botox®,  forms large complexes and composed of neurotoxin (NTX) as well as non-
toxic components.  We puriﬁed NTX lacking non-toxic components.  We investigated the eﬃcacy of this 
newly puriﬁed NTX for men with BPH.  Ten male patients (mean age,  70.0 years) with BPH received 
100 units (prostate volume [PV] ＜30ml) or 200 units (PV ｧ30ml) of NTX injected into the prostate via 
a minimally invasive outpatient technique.  Evaluation included uroﬂowmetry,  postvoid residual urine 
volume (PVR),  PV,  and International Prostate Symptom Score (IPSS) measured at baseline and 1,  3,  
6,  and 12 months post-treatment.  The status of 7 of the 10 patients examined was found to have 
improved within 1 month of treatment.  The mean IPSS decreased from 23.8±7.0 to 16.3±10.3 (p＝
0.0093) at 1 month,  to 14.9±8.2 (p＝0.0074) at 3 months,  and to 16.9±7.3 (p＝0.018) at 12 months.  The 
mean PV decreased from 47.8±21.2 to 39.2±19.5ml (p＝0.0076) at 3 months.  The PVR improved at 3 
and 6 months post-treatment.  Intraprostatic NTX injection induces prostate shrinkage and is eﬀective 
in men with BPH.
Key words: botulinum neurotoxin type A,  benign prostatic hyperplasia,  therapy
enign prostatic hyperplasia (BPH) is a chronic 
condition associated with lower urinary tract 
symptoms (LUTS).  Therapeutic options for LUTS 
associated with BPH have expanded rapidly in the last 
2 decades.  Treatment for BPH aims to relieve 2 types 
of urinary tract obstruction: mechanical urinary tract 
obstruction caused by tissue compression due to an 
enlarged prostate,  and functional urinary tract 
obstruction caused by constriction of the urinary tract 
and prostatic smooth muscle via sympathetic α1 adre-
noceptors (α1-AR).  As a result,  α1-AR blockers are 
widely recognized as the ﬁrst-line pharmacotherapy 
for BPH treatment [1].  Transurethral resection of 
the prostate remains the gold-standard surgical treat-
ment for BPH,  although this approach is being chal-
lenged by new minimally invasive treatments such as 
laser interventions.  The goals of therapy are to 
improve LUTS and minimize any adverse events of 
treatment.
　 Since clinical botulinum neurotoxin type A 
(BoNT/A) investigations into treatments for BPH 
started in 2003 [2],  several studies have demon-
strated the eﬃcacy of intraprostatic BoNT/A injec-
tion therapy for patients with BPH [3-8].  The 
B
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results of these studies have demonstrated that 
BoNT/A injection induced atrophy and diﬀuse apop-
tosis of the prostate gland and that the eﬀect persisted 
for at least 12 months without any notable side eﬀects 
[9].
　 There are several commercially available BoNT/A 
products worldwide.  Botox® and Dysport® are the 
most commonly used BoNT/A products available for 
urological use [10].  BoNT/A preparations of Botox® 
and Dysport® are progenitor neurotoxins (PTXs),  
which consist of both toxic and non-toxic components.  
The PTXs are found in 3 forms with molecular masses 
of 900kDa (19S),  500kDa (16S),  and 300kDa (12S).  
The PTXs dissociate into a neurotoxin (NTX) and a 
non-toxic component under alkaline conditions [11].  
As they are easily obtained and are more stable than 
NTXs,  PTXs are in clinical use.  However,  these 
PTXs induced side eﬀects in some patients in whom 
anti-PTX,  including anti-NTX antibodies,  are pro-
duced after the administration of several injections.  
Recently,  a pure NTX (Xeomin®) that is free from 
complexing proteins was made commercially available;  
the clinical eﬀectiveness of this product has been 
demonstrated [12,  13].  Using a simple procedure,  
our group also puriﬁed NTX lacking non-toxic compo-
nents,  and we previously reported its clinical eﬃcacy 
in refractory urge incontinence patients [14].  In this 
study,  we investigated the eﬀects of this newly puri-
ﬁed NTX in patients with symptomatic BPH.
Materials and Methods
　 Preparation of neurotoxin (NTX). NTX 
was obtained according to the following straightfor-
ward method.  After PTX consisting of toxic and non-
toxic components in 10mM sodium phosphate buﬀer 
(pH6.0) was applied to a lactose gel column equili-
brated with the same buﬀer (hemagglutinin-positive 
toxins bind to the column),  the pH of the column was 
then changed using 100mM sodium phosphate buﬀer 
(pH8.0).  Due to this change in pH,  the NTX dissoci-
ated from the non-toxic components on the column.  A 
non-toxic component-rich preparation was then eluted 
with a 10-mM sodium phosphate buﬀer (pH6.0) con-
taining 0.05 M lactose [11].
　 We examined the mutagenicity of NTX and the 
existence of prion protein and endotoxin prior to con-
ducting this human trial.  A mutagenicity assay 
(AMES test) of NTX (1,000 or 10,000 minimal lethal 
dose/ml) and albumin (50mg/ml) was performed 
according to the preincubation technique of Yahagi and 
colleagues [15].  Contamination of the NTX prepara-
tions (300µg/ml),  the hemagglutinin-positive progeni-
tor neurotoxin (19S and 16S; 0.3,  1,  3mg/ml),  and 
albumin (0.5,  5mg/ml) with prion protein was assayed 
using a Prionics-Check Western kit (Prionics AG,  
Schlieren,  Switzerland).  The NTX was ﬁltered with 
a 0.22-µm-pore-size membrane and then diluted to 
100,000 minimal lethal dose/ml in isotonic sodium 
chloride solution.  Contamination with endotoxin was 
determined by a Limulus amoebocyte lysate assay 
(BioWhittaker,  Walkersville,  MD,  USA) [16,  17].
　 Human trial. The eﬀects of NTX on the human 
prostate were evaluated in 10 men with symptomatic 
BPH who showed inadequate responses to α1-AR 
blockers.  The study was approved by the institutional 
review board of Kawasaki Medical School Hospital 
and written informed consent was obtained from all 
participants.
　 Ten patients,  aged 60 to 79 years old (median age,  
70),  were treated between October 2006 and November 
2007.  The patients had a complete urological assess-
ment before treatment,  which included measurement 
of serum prostatic speciﬁc antigen (PSA) level,  tran-
srectal ultrasonography,  and urine analysis.  All 
patients had an International Prostate Symptom 
Score (IPSS) of ｧ8 and a maximum urinary ﬂow rate 
(Qmax) of ｦ12ml/s.  At the time of enrollment,  all 
patients had stopped any prescription BPH medical 
therapy including α1-AR blockers,  and no BPH-
associated medical therapy was prescribed thereafter.  
All procedures were performed in the lithotomy posi-
tion,  with a transperineal (6 men) or transrectal (4 
men) approach under the guidance of transrectal ultra-
sonography,  and the procedure was carried out under 
a caudal block (1ｵ lidocaine 10ml).
　 NTX at 100 U (2 men,  for a prostate volume 
[PV] of ＜30ml) or 200 U (8 men,  for a PV of ｧ
30ml) was injected into the prostate.  The 100 U or 
200 U dose of NTX was dissolved in 4ml of saline 
immediately before treatment.  A 20-cm needle (21-G) 
was used,  and 2 injections of an equal volume (2ml) 
were administered into each lobe of the gland.  The 
patients were sent home without a catheter and were 
instructed to take 300mg of levoﬂoxacin orally for 2 
days.
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　 The evaluations included clinical determination of 
the IPSS,  quality of life (QOL) index,  maximum 
urinary ﬂow rate (Qmax),  postvoid residual urine 
volume (PVR) detected by ultrasonography,  and PV 
before treatment and 1 week,  1,  3,  6,  9,  and 12 
months post-treatment.  The PSA level was measured 
before treatment,  and 6 and 12 months post-treat-
ment.
　 Statistical analysis. Values are reported as 
the mean±standard deviation (SD).  The Wilcoxon 
signed rank test was used,  and a p-value of less than 
0.05 was considered signiﬁcant.
Results
　 At 1 week post-injection,  the mean IPSS and QOL 
index were signiﬁcantly improved (Table 1).  Four of 
10 patients reported an improvement in symptoms 
starting within 7 days post-NTX treatment.  Seven of 
the 10 patients noted an improvement within 1 month 
and were satisﬁed with this treatment.  Three patients 
were considered to have unchanged symptoms during 
the follow-up period.
　 The mean IPSS (for both storage and voiding 
symptoms) and QOL index signiﬁcantly improved from 
1 week to 12 months.  The mean IPSS decreased from 
23.8±7.0 to 16.3±10.3 (p＝0.0093) at 1 month,  to 
14.9±8.2 (p＝0.0074) at 3 months,  to 13.8±7.5 (p
＝0.0076) at 6 months,  and to 16.9±7.3 (p＝0.018) 
at 12 months.  The maximum eﬀect of the IPSS,  namely,  
a 42.0ｵ reduction,  was seen during the period from 
6 to 9 months.  However,  the eﬀect gradually decreased 
at 12 months.  The IPSS voiding symptoms signiﬁ-
cantly improved from 1 month to 12 months post-
injection.  The IPSS storage symptoms signiﬁcantly 
improved from 3 months to 12 months.  The maximum 
eﬀects for voiding and storage symptoms were 42.4ｵ 
and 49.4ｵ reductions from baseline,  respectively.  
The Qmax value signiﬁcantly improved only at 3 
months,  and PVR also improved at 3 and 6 months 
post-treatment (Table 1).  The maximum improvement 
in Qmax was 39.7ｵ from 6.3ml/s at baseline to 
8.8ml/s at 3 months (p＝0.0367).  The maximum 
reduction in PVR was 46.8ｵ from 99.5ml at baseline 
to 52.9ml at 6 months (p＝0.0152).  The PV 
decreased 18.0ｵ from 47.8ml at baseline to 39.2ml 
at 3 months post-treatment (p＝0.0076).  The mean 
total serum PSA decreased from 4.30ng/ml at base-
line to 3.75ng/ml at 6 months,  which corresponded to 
a 12.8ｵ reduction,  however,  this decrease was not 
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Table 1　 Patient proﬁles and results after NTX treatment
Number of
patients
IPSS
Storage, Voiding QOL Qmax (ml/s) PVR (ml) PV (ml) PSA (ng/ml)
Baseline 10 23.8±7.0 5.2±1.0　 6.3±3.1　 99.5±94.5　 47.8±21.2　 4.30±3.0
8.7±4.8, 11.8±3.4
1 week 10 19.4±9.3＊ 4.3±1.6＊ 5.5±2.0　 84.9±83.1　 45.9±22.3　 NA
7.2±4.5, 9.5±4.4
1 month 10 16.3±10.3＊ 3.4±1.6＊ 6.1±2.6　 101.5±97.0　 40.2±18.2＊ NA
6.7±5.4, 6.9±5.0＊
3 months 10 14.9±8.2＊ 3.3±1.8＊ 8.8±2.9＊ 65.3±73.6＊ 39.2±19.5＊ NA
5.3±3.8＊, 7.4±4.8＊
6 months 9 13.8±7.5＊ 3.2±1.6＊ 6.8±3.9　 52.9±62.5＊ 40.2±19.2＊ 3.75±2.2
4.4±3.5＊, 7.0±4.2＊
9 months 9 13.8±7.6＊ 3.7±1.4＊ 6.2±2.2　 86.3±100　 42.9±23.2　 NA
5.4±3.5＊, 6.8±4.5＊
12 months 8 16.9±7.3＊ 4.3±1.5＊ 7.2±4.0　 72.4±58.2　 41.0±17.0　 4.35±2.8
5.2±4.3＊, 7.4±4.6＊
NA: not available,  ＊Compared with the baseline,  p＜0.05
IPSS,  International Prostate Symptom Score; QOL,  quality of life; Qmax,  maximum urinary ﬂow rate; PVR,  postvoid residual urine 
volume; PV,  prostate volume; PSA,  prostatic speciﬁc antigen.
reach statistically signiﬁcant.
　 At a mean follow-up of more than 36 months,  5 of 
7 responsive patients reported a worsening of symp-
toms during the 12 months after treatment.  Finally,  5 
patients received transurethral holmium laser enucle-
ation of the prostate within 24 months post-treatment.  
No remarkable changes were observed in the histology 
of the resected prostatic tissue (data not shown).  No 
systemic side eﬀects were observed in this study.  One 
patient who had received a transrectal injection suf-
fered from prostatitis without fever,  and the patient 
received antibiotics for 1 week.
Discussion
　 BPH is a highly prevalent,  non-malignant enlarge-
ment of the prostate related to aging [18].  BPH may 
cause bladder outlet obstruction via 2 diﬀerent mecha-
nisms.  One mechanism is a static compression of the 
urethra by the prostatic adenoma,  and the other is a 
dynamic α1-AR-mediated sympathetic stimulation of 
the prostatic smooth muscle [19].  Prostatic tissue 
includes both the epithelial and stromal elements of the 
gland.  The epithelial elements are more sensitive to 
androgen deprivation,  and the stromal elements are 
more sensitive to α1-AR blockers.  Some researchers 
have suggested that prostate growth is controlled in an 
endocrine manner [20,  21].  There is also some evi-
dence that,  while the stromal component of the pros-
tate receives predominantly noradrenergic innervation,  
the epithelial component is innervated by autonomic 
nerves,  and cholinergic ﬁbers are thought to be 
responsible for acinar secretion.  BoNT/A,  which 
inhibits acetylcholine release at nerve terminals,  can 
suppress the secretory function of acetylcholine on the 
prostate,  and it has been shown to cause apoptosis of 
epithelial elements and a reduction in prostate weight 
[22,  23].  Prior to the present clinical study,  we had 
investigated this newly puriﬁed NTX,  and we demon-
strated volume reduction and apoptosis of the rat 
prostate after injection [24].  In the present study,  
NTX injection induced a 18ｵ reduction of PV at 3 
months.
　 Initially,  it was thought that BoNT/A could only 
act by inhibition of acetylcholine release at cholinergic 
neuromuscular junctions.  However,  the eﬀect was 
found to extend to the neuroglandular junction.  
Acetylcholine is not the only neurotransmitter aﬀected 
by BoNT/A.  Smith et al.  found that BoNT/A injec-
tion into the rat proximal urethral sphincter induces 
marked reductions in labeled norepinephrine after high 
(20Hz) electrical ﬁeld stimulation [25].  The inhibi-
tion of norepinephrine has attracted much interest in 
terms of the modulation of lower urinary tract dys-
function,  especially in men with BPH.  Moreover,  
BoNT/A has also been shown to inhibit the release of 
neuropeptides (e.g.,  calcitonin gene-related peptide) 
thought to play a role in overactive bladder conditions 
such as sensory urgency or chronic prostatitis [26,  
27].  For these reasons,  the use of BoNT/A has been 
extended to the treatment of symptomatic BPH.  
Indeed,  Chuang et al.  reported symptomatic relief 
after BoNT/A (Botox®) injection in patients without 
shrinkage of the prostate,  which can be explained by 
the induced relaxation of prostatic smooth muscle 
[4].
　 NTX was developed to reduce drug antigenicity by 
the removal of complexing proteins.  However,  with a 
size-reduced PTX component,  it could be hypothe-
sized that NTX may more rapidly and more easily 
diﬀuse away from the target tissue.  If such diﬀusion 
diﬀerences exist,  they would be expected to be associ-
ated with an adverse eﬀect proﬁle that would diﬀer 
from that of PTXs such as Botox®.  Although in this 
study,  we did not compare PTX and NTX,  our 
results were almost the same as those of previous 
studies that used PTX in human subjects [9].  
Moreover,  there were no signiﬁcant systemic compli-
cations in this study.  Commercially available NTX 
(Xeomin®) does not aﬀect the spread of NTX and it has 
been demonstrated that Xeomin® is not inferiority to 
Botox® in patients with cervical dystonia [12,  13].
　 Several clinical studies have demonstrated that 
beneﬁcial eﬀects were achieved with BoNT/A therapy 
(Table 2).  Currently,  α1-AR blockers remain the 
ﬁrst-line therapy for the majority of patients with 
BPH.  The total symptom score following medication 
is improved by 30 to 45ｵ,  and Qmax is improved by 
15 to 30ｵ versus baseline value [1].  With BoNT/A 
intraprostatic treatment,  the increase in Qmax (39.7-
121ｵ) and the decrease in IPSS (47.6-65.5ｵ) were 
statistically signiﬁcant in all studies reported to date.  
There is a statistically signiﬁcant reduction in PV,  
which varies from 13.3ｵ to 68.1ｵ (Table 2).  The 
reduction in PV appears to be more prominent in 
patients with a larger prostate [2,  5].  Although our 
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study demonstrated only an 18ｵ reduction in PV,  it 
was similar to that found by Kuo and Chuang et al. [4,  
5].  A recent randomized clinical trial demonstrated 
that BoNT/A (Botox®) treatment did not induce a 
decrease in prostate size [28].  In our previous animal 
study,  NTX injection induced marked atrophy and 
diﬀuse apoptosis of the rat prostate [24].  The rat 
prostate is primarily composed of epithelium,  whereas 
the human prostate is primarily stroma [21].  The 
pathology of BPH is heterogenous.  The ratio of epi-
thelium to stroma can vary substantially from 1 : 2 to 
1 : 5 in the human prostate [29].  The results of 
BoNT/A eﬀects in the rat prostate cannot be gener-
alized to the human therapeutic arena.  BoNT/A 
treatment of humans may relieve BPH symptoms by 
aﬀecting sensory nerve pathways rather than by 
reducing the prostatic size alone.
　 In previous study,  BoNT/A eﬀects appeared dur-
ing the ﬁrst week to 1 month post-treatment [3,  5].  
In this study,  the beneﬁcial results were evident 
within 1 week post-treatment,  and they continued for 
12 months.  However,  5 of 7 responsive patients 
complained of a recurrence of LUTS at 12 months.  
Finally,  5 patients underwent transurethral holmium 
laser enucleation of the prostate and were very satis-
ﬁed with the results.  In contrast,  Silva et al. reported 
11 of 21 frail elderly patients with refractory urinary 
retention resumed spontaneous voiding after BoNT/A 
(Botox®) injection and subjective and objective 
improvement was limited [8].  The ﬁrst randomized,  
placebo-controlled study showed prostatectomy-like 
results,  but these results were suspected as being too 
good to be true [2,  9].  Thus,  the eﬀectiveness of 
BoNT/A injection may lie between that of medication 
and prostatectomy.  Intraprostatic BoNT/A injection 
may be a therapeutic option for patients with refrac-
tory BPH who do not elect to undergo surgery.
　 The therapeutic eﬃcacy BoNT/A is related to 
injection dosage,  diﬀusion of toxin within the prostate,  
the ratio of epithelium and stromal components,  and 
to detrusor function.  In this study,  the improvements 
in subjective symptoms and objective parameters were 
almost the same as those previously reported (Table 
2).  Two of 3 non-responders were suspected to be 
weak detrusors by urodynamic study,  and another 
patient demonstrated typical middle lobe hypertrophy.  
There is a possibility that some patients will experi-
ence less beneﬁt than others from BoNT/A treat-
ment.
　 The eﬀects of denervation provided by BoNT/A 
wear oﬀ as new axons re-sprout at around 6 months.  
Chuang et al.  and Maria et al.  reported that the treat-
ment eﬀect emerged at 1 month and was sustained for 
at least 12 months [3,  6].  In the present study,  
maximum eﬀects were seen from 3 to 9 months,  and 
PV reached a minimum at 3 to 6 months.  Silva et al.  
[8] reported that PV decreased gradually to a mini-
mum at 6 months,  corresponding to a 40ｵ reduction.  
From 6 months onwards,  a slow re-growth of the 
glands was observed.  Thus,  the previous ﬁnding by 
Silva et al.  [8] was almost the same as that obtained 
in our study.
　 The present human study had some limitations.  
First,  it lacked a placebo control group.  Second,  no 
comparison was made between the eﬀects of doses of 
100 U and 200 U,  nor between the eﬀects of tran-
srectal versus transperineal approaches.  As the pres-
ent study was too small for such comparisons to be 
made,  further investigations will be necessary.  We 
are currently planning to examine whether there are 
any diﬀerences in the respective modes of action of 
PTX and NTX therapies.
　 In conclusion,  our preliminary results demon-
strated that newly puriﬁed NTX improved the symp-
toms of BPH-related LUTS to the same extent as that 
achieved with PTX.  A newly puriﬁed intraprostatic 
NTX injection may be a therapeutic option for patients 
with refractory BPH.
References
 1. Djavan B and Marberger M: A meta-analysis on the eﬃcacy and 
tolerability of alpha 1-adrenoceptor antagonists in patients with lower 
urinary tract symptoms suggestive of benign prostatic obstruction.  
Eur Urol (1999) 36: 1-13.
 2. Maria G,  Brisinda G,  Civello IM,  Bentivoglio AR,  Sganga G and 
Albanese A: Relief by botulinum toxin of voiding dysfunction due 
to benign prostatic hyperplasia: results of a randomized,  placebo-
controlled study.  Urology (2003) 62: 259-264.
 3. Kuo HC: Prostate botulinum toxin injection-an alternative treat-
ment for benign prostatic obstruction in poor surgical candidates.  
Urology (2005) 65: 670-674.
 4. Chuang YC,  Chiang PH,  Huang CC,  Hsien K,  Yoshimura N and 
Chancellor MB: Botulinum toxin A improves benign prostatic hyper-
plasia symptoms in patients with small prostates.  Urology (2005) 
66: 775-779.
 5. Guercini F,  Giannantoni A,  Bard RL,  Brisinda G,  Cadeddu F,  
Maria G and Rossi P: Intraprostatic botulinum toxin injection in 
patients with severe benign prostatic hyperplasia a multicenter fea-
sible study (Abstract).  J Urol (2005) 173 (suppl): 376-377.
296 Acta Med.  Okayama　Vol.  66,  No.  4Yokoyama et al.
 6. Chuang YC,  Chiang PH,  Yoshimura N,  Miguel FD and Chancellor 
MB: Sustained beneﬁcial eﬀects of intraprostatic botulinum toxin 
type A on lower urinary tract symptoms and quality of life in men 
with benign prostatic hyperplasia.  BJU Int (2006) 98: 1033-1037.
 7. Brisinda G,  Cadeddu F,  Vanella S,  Mazzeo P,  Marniga G and 
Maria G: Relief by botulinum toxin of lower urinary tract symptoms 
owing to benign prostatic hyperplasia: early and long-term results.  
Urology (2009) 73: 90-94.
 8. Silva J,  Pinto R,  Carvalho T,  Botelho F,  Silva P,  Oliveira R,  
Silva C,  Cruz F and Dinis P: Intraprostatic botulinum toxin type A 
injection in patients with benign prostatic enlargement: duration of 
the eﬀect of a single treatment.  BMC Urology (2009) 9: 9.
 9. Oeconomou A,  Madersbacher H,  Kiss G,  Berger TJ,  Melekos M 
and Rehder P: Is botulinum neurotoxin type A (BoNT-A) a novel 
therapy for lower urinary tract symptoms due to benign prostatic 
enlargement? A review of the literature.  Eur Urol (2008) 54: 765-
777.
10. Chuang YC and Chancellor MB: The application of botulinum 
toxin in the prostate.  J Urol (2006) 176: 2375-2382.
11. Oguma K,  Inoue K,  Fujinaga Y,  Yokota K,  Watanabe T,  Ohyama T,  
Takeshi K and Inoue K: Structure and function of Clostridium botu-
linum progenitor toxin.  J Toxicol-Toxin Rev (1999) 18: 17-34.
12. Frevert J: Xeomin®: an innovative new botulinum toxin type A.  
Eur J Neurology (2009) 16 Suppl.  2: 11-13.
13. Dressler D: Routine use of Xeomin® in patients previously treated 
with Botox®: long term results.  Eur J Neurology (2009) 16 
(Supp. 2): 2-5.
14. Lee JC,  Yokoyama T,  Hwang HJ,  Arimitsu H,  Yamamoto Y,  
Takigawa T,  Takeshi K,  Nishikawa A,  Kumon K and Oguma K:  
Clinical application of Clostridium botulinum type A neurotoxin 
puriﬁed by a simple procedure for patients with urinary inconti-
nence caused by refractory destrusor overactivity.  FEMS Immunol 
Med Microbiol (2007) 51: 201-211.
15. Yahagi T,  Nagao M,  Seino Y,  Matsushima T and Sugimura T:  
Mutagenicities of N-nitrosamines on Salmonella.  Mutat Res (1977) 
48: 121-129.
16. Gao B and Tsan MF: Recombinant human heat shock protein 60 
does not induce the release of tumor necrosis factor from murine 
macrophages.  J Biol Chem (2003) 25: 22523-22529.
17. De Haan L,  Hearn AR,  Rivett AJ and Hirst TR: Enhanced delivery 
of enogenous peptides into the class I antigen processing and pre-
sentation pathway.  Infect Immun (2002) 70: 3249-3258.
18. Jacobsen SJ,  Girman CJ and Lieber MM: Natural history of benign 
prostatic hyperplasia.  Urology (2001) 58: 5-16.
19. Lepor H,  Tang R and Shapiro E: The α-adrenoceptor subtype 
mediating thetension of human prostatic smooth muscle.  Prostate 
(1993) 22: 301-307.
20. Ventura S,  Pennefather JN and Mitchelson F: Cholinergic inner-
vation and function in the prostate gland.  Pharmacol Ther (2002) 
94: 93-112.
21. Luján M,  Páez A,  Llanes L,  Angulo J and Berenguer A: Role of 
autonomic innervation in rat prostatic structure maintenance: a 
morphometric analysis J Urol (1998) 160: 1919-1923.
22. Doggweiler R,  Zermann DH,  Ishigooka M and Schmidt RA:  
Botox-induced prostatic involution.  Prostate (1998) 37: 44-50.
23. Chuang YC,  Huang CC,  Kang HY,  Chiang PH,  Demiguel F,  
Yoshimura N and Chancellor MB: Novel action of botulinum toxin 
on the stromal and epithelial components of the prostate gland.  J 
Urol (2006) 175: 1158-1163.
24. Nishiyama Y,  Yokoyama T,  Tomizawa K,  Okamura K,  Yamamoto Y,  
Matsui H,  Oguma K,  Nagai A and Kumon H: The eﬀects of puri-
ﬁed newly developed botulinum neurotoxin type A in the rat pros-
tate.  Urology (2009) 74: 436-439.
25. Smith CP,  Franks ME,  McNeil BK,  Ghosh R,  de Groat WC,  
Chancellor MB and Somogyi GT: Eﬀects of botulinum toxin A on 
the autonomic nervous system of the rat lower urinary tract.  J Urol 
(2003) 169: 1896-1901.
26. Rapp DE,  Turk KW,  Bales GT and Cook SP: Botulinum toxin type 
a inhibits calcitonin gene related peptide release from isolated rat 
bladder.  J Urol (2006) 175:1138‒1142.
27. Chuang YC,  Yoshimura N,  Huang CC,  Chiang PH and Chancellor 
MB: Intravesical botulinum toxin A administration produces anal-
gesia against acetic acid induced bladder pain responses in rats.  J 
Urol (2004) 172: 1529‒1532.
28. Crawford ED,  Hirst K,  Kusek JW,  Donnell RF,  Kaplan SA,  
McVary KT,  Mynderse LA,  Roehborn CG,  Smith CP and 
Bruskewitz R: Eﬀects of 100 and 300 units of onabotulinum toxin 
A on lower urinary tract symptoms of benign prostatic 
hyperplasia: a phase 2 randomized clinical trial.  J Urol (2011) 
186: 965-970.
29. Kyprianou N: Doxazosin and terazosin suppress prostate growth 
by inducing apoptosis: clinical signiﬁcance.  J Urol (2003) 19:  
1520-1525.
297A Newly Puriﬁed Botulinum Neurotoxin for BPHAugust 2012
